Fig. 1

High expression of HMGA2 correlates with worse clinical outcomes in endometrial cancer patients. a and b HMGA2 was up-regulated in endometrial carcinoma tissues (n = 40) compared with normal tissues (n = 37). Data are presented as the mean ± SEM. c Disease-free survival curves for HMGA2 mRNA in 40 endometrial carcinoma cases. d The expression of HMGA2 was detected via immunohistochemistry in endometrial cancer (n = 80) and normal endometrial tissue (n = 19). e Disease-free survival curves for HMGA2 protein in 80 endometrial carcinoma cases. f Compared with normal endometrial tissue (n = 35), (the controls were collected from paracancerous tissues in patients with endometrial cancer). HMGA2 was highly expressed in 552 endometrial carcinoma samples (TCGA cohort). g HMGA2 expression levels in patients with different clinical stages of endometrial cancer (TCGA cohort): normal (n = 35), I (n = 339), II (n = 48), III & IV (n = 153). h HMGA2 expression levels in patients with endometrial cancers of different grades (TCGA cohort): G1 (n = 109), G2 (n = 120), G3 (n = 314). i Myometrial invasion (TCGA cohort): < 1/2 group (n = 259), ≥ 1/2 group (n = 211). j Lymph node status (TCGA cohort): negative group (n = 190), positive group (n = 322). k ROC of HMGA2 (TCGA cohort). l High expression of HMGA2 predicted a shorter overall survival in endometrial cancer. The data were retrieved and analysed from the TCGA dataset (n = 542). *P < 0.05, **P < 0.01, ***P < 0.0001